retatrutide clinical trial results Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the A new clinical trial from
Pay in 4 interest-free payments of $6.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5




























